Display options
Cite
Giannaccare G, Ghelardini C, Mancini A, et al. New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease. J Clin Med. 2021;11(1)doi: 10.3390/jcm11010108.
Giannaccare, G., Ghelardini, C., Mancini, A., Scorcia, V., & Di Cesare Mannelli, L. (2021). New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease. Journal of clinical medicine, 11(1), . https://doi.org/10.3390/jcm11010108
Giannaccare, Giuseppe, et al. "New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease." Journal of clinical medicine vol. 11,1 (2021). doi: https://doi.org/10.3390/jcm11010108
Giannaccare G, Ghelardini C, Mancini A, Scorcia V, Di Cesare Mannelli L. New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease. J Clin Med. 2021 Dec 25;11(1). doi: 10.3390/jcm11010108. PMID: 35011849; PMCID: PMC8745516.
Copy Download .nbib Format: NLM
Share it on

J Clin Med. 2021 Dec 25;11(1). doi: 10.3390/jcm11010108.

New Perspectives in the Pathophysiology and Treatment of Pain in Patients with Dry Eye Disease.

Journal of clinical medicine

Giuseppe Giannaccare, Carla Ghelardini, Alessandra Mancini, Vincenzo Scorcia, Lorenzo Di Cesare Mannelli

Affiliations

  1. Department of Ophthalmology, University Magna Graecia of Catanzaro, 88100 Catanzaro, Italy.
  2. Department of Neuroscience, Psychology, Drug Research and Child Health-NEUROFARBA-Pharmacology and Toxicology Section, University of Florence, 50139 Florence, Italy.

PMID: 35011849 PMCID: PMC8745516 DOI: 10.3390/jcm11010108

Abstract

Ocular discomfort and eye pain are frequently reported by patients with dry eye disease (DED), and their management remains a real therapeutic challenge for the Ophthalmologist. In DED patients, injury at the level of each structure of the ocular surface can determine variable symptoms, ranging from mild ocular discomfort up to an intolerable pain evoked by innocuous stimuli. In refractory cases, the persistence of this harmful signal is able to evoke a mechanism of maladaptive plasticity of the nervous system that leads to increased pain responsiveness. Peripheral and, subsequently, central sensitization cause nociceptor hyperexcitability and persistent pain perception that can culminate in the paradoxical situation of perceiving eye pain even in the absence of ocular surface abnormalities. Effective therapeutic strategies of these cases are challenging, and new options are desirable. Recently, a theoretical novel therapeutic approach concerns enkephalins thanks to the evidence that eye pain sensations are modulated by endogenous opioid peptides (enkephalins, endorphins and dynorphins). In this regard, new topical agents open up a new theoretical scenario in the treatment of ocular discomfort and eye pain in the setting of DED, such as, for example, a multimolecular complex based on proteins and glycosaminoglycans also containing opiorphin that may assist the physiological pain-relieving mechanism of the eye.

Keywords: dry eye disease; glicopro; neuropathic pain; opiorphin; pain

References

  1. Cornea. 2019 Nov;38(11):1412-1417 - PubMed
  2. Graefes Arch Clin Exp Ophthalmol. 2019 Mar;257(3):583-589 - PubMed
  3. J Optom. 2017 Jan - Mar;10(1):5-13 - PubMed
  4. Arch Oral Biol. 2019 Mar;99:15-21 - PubMed
  5. Ocul Surf. 2006 Jul;4(3):155-61 - PubMed
  6. Br J Ophthalmol. 2021 Apr;105(4):446-453 - PubMed
  7. Pain. 2019 Feb;160(2):307-321 - PubMed
  8. Invest Ophthalmol Vis Sci. 2016 Feb;57(2):617-25 - PubMed
  9. Front Cell Dev Biol. 2020 Aug 07;8:731 - PubMed
  10. Future Sci OA. 2015 Nov 01;1(3):FSO2 - PubMed
  11. Ocul Surf. 2017 Jul;15(3):276-283 - PubMed
  12. Biomed Pharmacother. 2020 Dec;132:110794 - PubMed
  13. Int J Mol Sci. 2017 Jun 29;18(7): - PubMed
  14. J Clin Med. 2019 Sep 17;8(9): - PubMed
  15. Br J Anaesth. 2011 Jul;107(1):19-24 - PubMed
  16. Ann Clin Biochem. 2018 Sep;55(5):561-570 - PubMed
  17. Eye Brain. 2018 Jun 28;10:37-45 - PubMed
  18. Int J Mol Sci. 2020 Dec 04;21(23): - PubMed
  19. J Physiol Pharmacol. 2010 Aug;61(4):483-90 - PubMed
  20. Ocul Surf. 2021 Jul;21:107-117 - PubMed
  21. Behav Brain Res. 2010 Nov 12;213(1):88-93 - PubMed
  22. Br J Ophthalmol. 2021 Apr 30;: - PubMed
  23. Transfus Apher Sci. 2017 Aug;56(4):595-604 - PubMed
  24. Cornea. 2020 Nov;39(11):1377-1380 - PubMed
  25. Br J Ophthalmol. 1994 Feb;78(2):138-41 - PubMed
  26. Proc Natl Acad Sci U S A. 2006 Nov 21;103(47):17979-84 - PubMed
  27. Pharmaceutics. 2021 Dec 13;13(12): - PubMed
  28. Invest Ophthalmol Vis Sci. 2005 Jul;46(7):2341-5 - PubMed
  29. Front Cell Neurosci. 2020 Dec 10;14:610342 - PubMed
  30. Clin Oral Investig. 2017 Sep;21(7):2363-2370 - PubMed
  31. Peptides. 2009 Jul;30(7):1348-54 - PubMed
  32. Cornea. 2004 Jul;23(5):527-9 - PubMed
  33. Peptides. 2016 Feb;76:57-64 - PubMed
  34. Mol Pain. 2015 Apr 21;11:21 - PubMed
  35. Ocul Surf. 2009 Jan;7(1):28-40 - PubMed
  36. Exp Eye Res. 2016 Aug;149:100-106 - PubMed
  37. Albrecht Von Graefes Arch Klin Exp Ophthalmol. 1975 Oct 17;197(1):71-81 - PubMed
  38. Med Sci (Paris). 2007 Jan;23(1):37-9 - PubMed

Publication Types